Literature DB >> 17991785

MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy.

Aldo Quattrone1, Giuseppe Nicoletti, Demetrio Messina, Francesco Fera, Francesca Condino, Pierfrancesco Pugliese, Pierluigi Lanza, Paolo Barone, Letterio Morgante, Mario Zappia, Umberto Aguglia, Olivier Gallo.   

Abstract

PURPOSE: To prospectively assess sensitivity and specificity of magnetic resonance (MR) imaging measurements of midbrain, pons, middle cerebellar peduncles (MCPs), and superior cerebellar peduncles (SCPs) for differentiating progressive supranuclear palsy (PSP) from Parkinson disease (PD) and Parkinson variant of multiple system atrophy (MSA-P), with established consensus criteria as reference standard.
MATERIALS AND METHODS: All study participants provided informed consent; study was approved by the institutional review board. Pons area, midbrain area, MCP width, and SCP width were measured in 33 consecutive patients with PSP (16 possible, 17 probable), 108 consecutive patients with PD, 19 consecutive patients with MSA-P, and 50 healthy control participants on T1-weighted MR images. The pons area-midbrain area ratio (P/M) and MCP width-SCP width ratio (MCP/SCP) were also used, and an index termed MR parkinsonism index was calculated [(P/M).(MCP/SCP)]. Differences in MR imaging measurements among groups were evaluated with Kruskal-Wallis test, Mann-Whitney U test, and Bonferroni correction.
RESULTS: Midbrain area and SCP width in patients with PSP (23 men, 10 women; mean age, 69.3 years) were significantly (P < .001) smaller than in patients with PD (62 men, 46 women; mean age, 65.8 years), patients with MSA-P (five men, 14 women; mean age, 64.0 years), and control participants (25 men, 25 women; mean age, 66.6 years). P/M and MCP/SCP were significantly larger in patients with PSP than in patients in other groups and control participants. All measurements showed some overlap of values between patients with PSP and patients from other groups and control participants. MR parkinsonism index value was significantly larger in patients with PSP (median, 19.42) than in patients with PD (median, 9.40; P < .001), patients with MSA-P (median, 6.53; P < .001), and control participants (median, 9.21; P < .001), without overlap of values among groups. No patient with PSP received a misdiagnosis when the index was used (sensitivity and specificity, 100%).
CONCLUSION: The MR parkinsonism index can help distinguish patients with PSP from those with PD and MSA-P on an individual basis. RSNA, 2007

Entities:  

Mesh:

Year:  2007        PMID: 17991785     DOI: 10.1148/radiol.2453061703

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  113 in total

1.  Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials.

Authors:  Jennifer L Whitwell; Jia Xu; Jay N Mandrekar; Jeffrey L Gunter; Clifford R Jack; Keith A Josephs
Journal:  Parkinsonism Relat Disord       Date:  2011-11-13       Impact factor: 4.891

2.  Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging.

Authors:  Kazumichi Tsukamoto; Eiji Matsusue; Yoshiko Kanasaki; Suguru Kakite; Shinya Fujii; Toshio Kaminou; Toshihide Ogawa
Journal:  Neuroradiology       Date:  2012-01-25       Impact factor: 2.804

3.  Magnetic resonance imaging in progressive supranuclear palsy.

Authors:  M Stamelou; S Knake; W H Oertel; G U Höglinger
Journal:  J Neurol       Date:  2010-12-22       Impact factor: 4.849

Review 4.  Differences between conventional and nonconventional MRI techniques in Parkinson's disease.

Authors:  A Baglieri; M A Marino; R Morabito; G Di Lorenzo; P Bramanti; S Marino
Journal:  Funct Neurol       Date:  2013 Apr-May

5.  Improved Automatic Morphology-Based Classification of Parkinson's Disease and Progressive Supranuclear Palsy.

Authors:  Aron S Talai; Zahinoor Ismail; Jan Sedlacik; Kai Boelmans; Nils D Forkert
Journal:  Clin Neuroradiol       Date:  2018-09-14       Impact factor: 3.649

6.  MRI Planimetry and Magnetic Resonance Parkinsonism Index in the Differential Diagnosis of Patients with Parkinsonism.

Authors:  V C Constantinides; G P Paraskevas; G Velonakis; P Toulas; E Stamboulis; E Kapaki
Journal:  AJNR Am J Neuroradiol       Date:  2018-04-05       Impact factor: 3.825

7.  Slowly progressive aphemia: a neuropsychological, conventional, and functional MRI study.

Authors:  R Gallassi; L Sambati; R Poda; F Oppi; M Stanzani Maserati; D Cevolani; R Agati; R Lodi
Journal:  Neurol Sci       Date:  2011-05-24       Impact factor: 3.307

Review 8.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

9.  Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study.

Authors:  Salvatore Nigro; Angelo Antonini; David E Vaillancourt; Klaus Seppi; Roberto Ceravolo; Antonio P Strafella; Antonio Augimeri; Andrea Quattrone; Maurizio Morelli; Luca Weis; Eleonora Fiorenzato; Roberta Biundo; Roxana G Burciu; Florian Krismer; Nikolaus R McFarland; Christoph Mueller; Elke R Gizewski; Mirco Cosottini; Eleonora Del Prete; Sonia Mazzucchi; Aldo Quattrone
Journal:  Mov Disord       Date:  2020-02-24       Impact factor: 10.338

10.  The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy.

Authors:  Luke A Massey; Hans R Jäger; Dominic C Paviour; Sean S O'Sullivan; Helen Ling; David R Williams; Constantinos Kallis; Janice Holton; Tamas Revesz; David J Burn; Tarek Yousry; Andrew J Lees; Nick C Fox; Caroline Micallef
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.